New onset diabetes and atypical antipsychotics

European Neuropsychopharmacology

Volumn 11, Issue 1, 2001, Pages 25-32

  Liebzeit, Krystal A ^a   Markowitz, John S ^a,d   Caley, Charles F ^b,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c INSTITUTE OF LIVING   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antipsychotics; New onset diabetes; Typical and atypical

Indexed keywords

CLOZAPINE; OLANZAPINE; PHENOTHIAZINE; QUETIAPINE; RISPERIDONE;

DIABETES MELLITUS; DIABETIC KETOACIDOSIS; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 0035101207     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(00)00127-9     Document Type: Article

References (50)

1. Bodyweight gain induced by psychotropic drugs: Incidence, mechanisms and management
2. Diabetic ketoacidosis and clozapine
3. Antipsychotic-induced weight gain: A comprehensive research synthesis
4. Diabetes mellitus as a side effect of treatment with tricyclic neuroleptics
5. Economic consequences of diabetes mellitus in the U.S. in 1997
6. ®) product information
7. Radioreceptor binding profile of the atypical antipsychotic olanzapine
8. 2 receptor agonists DOI and α-methyl-5-HT on plasma glucose and insulin levels in the rat
9. Diabetic ketoacidosis associated with clozapine treatment
10. Relationship of phenothiazine intake and psychiatric diagnosis to glucose level and tolerance
11. Hyperglycemia associated with olanzapine
12. Diabetic ketoacidosis with olanzapine treatment
13. Clozapine-associated elevation in serum triglycerides
14. Serum triglyceride levels in patients treated with clozapine
15. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment
16. Hyperglykämie und ketoazidose unter olanzapin
17. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications
18. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five year naturalistic study
19. Medical comorbidity in schizophrenia
20. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women
21. Severe hyperglycemia associated with high doses of clozapine
22. Cardiovascular and respiratory risk factors and symptoms among general practice patients with long-term medical illness
23. Lactic acidosis and fatal myocardial failure due to clozapine
24. Chlorpromazine induced diabetes
25. Ketoacidosis as a side-effect of clozapine: a case report
26. Diabetic ketoacidosis associated with clozapine treatment
27. Olanzapine-induced ketoacidosis with diabetes mellitus
28. Atypical antipsychotics Part I: pharmacology, pharmacokinetics, and efficacy
29. Diabetic ketoacidosis with clozapine treatment
30. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychosis
31. Schizophrenia and diabetes mellitus
32. Diabetes mellitus in schizophrenic patients
33. Hyperglycemia and olanzapine
34. Olanzapine increases weight and trigylcerides
35. Diabetic ketoacidosis from clozapine and lithium cotreatment
36. Clozapine monotherapy and ketoacidosis
37. Clozapine and associated diabetes mellitus
38. Effect of clozapine-quetiapine combination therapy on weight and glycemic control
39. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding
40. Impaired glucose tolerance and abnormal movements in patients with schizophrenia
41. Blood sugar levels in patients with chlorpromazine
42. Clozapine-induced diabetic ketoacidosis
43. New-onset diabetes mellitus associated with the initiation of quetiapine treatment
44. Phenothiazines and diabetes in hospitalized women
45. Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment
46. Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin and glucagon in the rat
47. Novel antipsychotics and new onset diabetes
48. Novel antipsychotics: comparison of weight gain liabilities
49. Hyperglycemic properties of serotonin receptor antagonists
50. The effect of clozapine on glucose metabolism